Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[13/07/2018]

UCB : UCB Media Room: BLA Resubmission for Evenity to US FDA

UCB and Amgen Resubmit Biologics Licence Application BLA for EVENITYTM Romosozumab to the U.S. FDABLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 PatientsBrussels, Belgium and Thousand Oaks, CalifJuly 13, 2018, 07:00 CET – UCB Euronext Brussels: UCB and Amgen NASDAQ:AMGN today announced the resubmission of the Biologics License Application BLA to the U.S. Food and Drug... See more
 
UCB [BE0003739530/UCB]   
[06/07/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.2 notifications referring to situation on 29 June and 2 July 2018Threshold crossed: 5%Latest shareholding: 4,91%Brussels Belgium, 6 July 2018 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2... See more
 
UCB [BE0003739530/UCB]   
[02/07/2018]

UCB : UCB Media Room: Neupro Approval in China

UCB announces approval of NEUPRO® in China to treat Parkinson’s DiseaseNEUPRO now approved in China for the treatment of the signs and symptoms of earlystage idiopathic Parkinson’s Disease as monotherapy i.e. without levodopa or in combination with levodopaNEUPRO approval in China reinforces UCB’s ongoing commitment to supporting patient value across China and to offering Chinese patients... See more
 
UCB [BE0003739530/UCB]   
[28/06/2018]

UCB : UCB Media Room: IFPA 2018 Data Release

New UCB Research Showcases Value of CIMZIA® certolizumab pegol in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient PopulationsCIMZIA, the only Fcfree, PEGylated antiTNF, recently received marketing authorization from the European Commission for the treatment of adults with moderate to severe plaque psoriasisBrussels, Belgium – 28 June 2018 – UCB, a global... See more
 
UCB [BE0003739530/UCB]   
[15/06/2018]

UCB : UCB Media Room: EULAR 2018 AIM Survey

New Study Presented at the Annual European Congress of Rheumatology EULAR 2018 Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy JourneySurvey reveals that women of childbearing age with chronic rheumatic diseases experience unique challenges, and suggests many experience a lack of guidance and consistent information regarding family planning and treatment during... See more